Richard Rosenquist Brandell

Richard Rosenquist Brandell

Professor/Senior Physician
Visiting address: Karolinska Institutet, BioClinicum J10:20, Visionsgatan 4, 17164 Solna
Postal address: K1 Molekylär medicin och kirurgi, K1 MMK Klinisk genetik, 171 76 Stockholm
Part of:

About me

  • Richard Rosenquist Brandell was recently appointed Professor of Clinical Genetics at the Department of Molecular Medicine and Surgery, Karolinska Institutet and Senior Physician in Clinical Genetics at Karolinska University Hospital, Sweden. He received his medical degree (1996) and PhD degree (1998) at Umeå University, Sweden, undertook a postdoctoral period at the Department of Pathology, Frankfurt am Main, Germany, and became specialist in Clinical Genetics 2004. Richard Rosenquist Brandell started his own research group at Uppsala University in 2000, focusing on molecular characterization of lymphoid malignancies, and his group rapidly became internationally renowned. He became Professor of Molecular Hematology in 2007 at the Department of Immunology, Genetics and Pathology, Uppsala University. He has initiated and led the SciLifeLab Clinical Genomics Facility in Uppsala between 2013-2017 and is currently Platform Director for the national Diagnostics Development Platform within SciLifeLab. More recently, he is coordinating the Genomics Medicine Sweden initiative that aims to build a new type of infrastructure within Swedish healthcare that implements precision medicine at a national level.

    By employing a translational approach and utilizing cutting‐edge molecular tools, including next-generation sequencing technologies, Richard Rosenquist Brandell has made outstanding contributions to our understanding of the mechanisms behind the development of chronic lymphocytic leukemia (CLL), the most common adult leukemia. His studies have identified novel prognostic and predictive markers, defined new clinically relevant CLL subgroups, as well as provided significantly improved risk stratification at the individual patient level. Even more importantly, Rosenquist Brandell’s team has presented compelling evidence for a role of antigens (both autoantigens and microbial antigens) in the pathogenesis of CLL, which has generated great interest internationally. He has also built competitive networks at the national, European and international level. He is one of five founding members of an eminent European network of CLL researcher with an impressive combined cohort of more than 34, 000 CLL patients from 24 academic institutions.

Research

  • Research group leader of the group Clinical Genetics

Teaching

  • Richard Rosenquist Brandell has successfully supervised 23 PhD students as well as seven postdocs, and his research has resulted in more than 200 peer-reviewed papers. He was recently selected as Wallenberg Clinical Scholars 2017 by the Knut and Alice Wallenberg Foundation.

Articles

All other publications

Grants

  • The molecular landscape of chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2018
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively kind disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example, the time for treatment to be inserted or total survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to determine in advance whether a particular subgroup of patients benefit from a particular treatment, something that is not possible at present.
  • The molecular landscape of chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2017
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively kind disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example, the time for treatment to be inserted or total survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to determine in advance whether a particular subgroup of patients benefit from a particular treatment, something that is not possible at present.
  • The molecular landscape of chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2016
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively kind disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example, the time for treatment to be inserted or total survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to determine in advance whether a particular subgroup of patients benefit from a particular treatment, something that is not possible at present.
  • Characterization of the molecular landscape in chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2015
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively "kind" disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example the time for treatment to be inserted or survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to predetermine whether a particular subgroup of patients benefit from a certain treatment, something that is not possible at present.
  • Characterization of the molecular landscape in chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2014
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively "kind" disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example the time for treatment to be inserted or survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to predetermine whether a particular subgroup of patients benefit from a certain treatment, something that is not possible at present.

News from KI

Events from KI